TB vaccine linked to lower risk of contracting COVID-19
A widely used tuberculosis vaccine is associated with reduced likelihood of contracting COVID-19 (coronavirus), according to a new study by Cedars-Sinai.
A widely used tuberculosis vaccine is associated with reduced likelihood of contracting COVID-19 (coronavirus), according to a new study by Cedars-Sinai.
Article written by Christine Clark and Colin Brown We are hearing almost hourly warnings of how the NHS will soon be overwhelmed with Covid-19 cases. Yet we have… read more.
When a virus enters the body, it is picked up by certain cells of the immune system. They transport the virus to the lymph nodes where they present… read more.
Article written by Gary Finnegan. The European Medicines Agency (EMA) has given the green light for ten new medicines at the latest meeting of its influential Committee for… read more.
Article written by Gary Finnegan There are seven ‘forms of disease’ in people with mild COVID-19, according to scientists at the Medical University of Vienna.
Sex, age, and severity of disease may be useful in identifying COVID-19 survivors who are likely to have high levels of antibodies that can protect against the disease,… read more.
Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19. According to the first findings from a global registry… read more.
A comprehensive international study, led by Monash University researchers, has definitively found that pregnancy can delay the onset of multiple sclerosis (MS) by more than 3 years. MS… read more.
Moderna announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up to $472 million to support late… read more.
Moderna, Inc. announced the publication of an interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, in The New England Journal of… read more.
Results of a global survey of 1,375 adults aged at least 45 years old and living with Chronic Obstructive Pulmonary Disease (COPD) in 11 countries have been published… read more.
Regeneron Pharmaceuticals, Inc. announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron’s investigational double antibody cocktail for the treatment and prevention of COVID-19 . A Phase III… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.